← Leaderboards
Silvia V Montaner
University Of Maryland Baltimore
$5,183,344
Attributed
$6,319,200
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $584.6K · FY2007–24$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,319,200 · 3
By mechanism
R01$6,319,200 · 3
Top collaborators
- Akrit Singh Sodhi4 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Vincent Michael Bruno$8,178,836
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelIn VitroTherapeutic TargetInsightPathogenesisMolecularInvestigationTissuesBaseEndothelial CellsMediatingGenesCytokineMolecular TargetSignal PathwayAngiogenic FactorNeuropilin-1DesignBlood VesselsNovel TherapeuticsIn VivoBindingAngptl4 GeneClinical Management
Grant awards (15)
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$584,568
R01 · FY2024 · EY · contact PI
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$578,018
R01 · FY2023 · EY · contact PI
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$557,501
R01 · FY2022 · EY · contact PI
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$551,625
R01 · FY2021 · EY · contact PI
Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4$511,146
R01 · FY2020 · EY · contact PI
Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4$70,798
R01 · FY2020 · EY · contact PI
Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4$511,146
R01 · FY2019 · EY · contact PI
Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4$511,146
R01 · FY2018 · EY · contact PI
Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4$510,952
R01 · FY2017 · EY · contact PI
Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4$530,014
R01 · FY2016 · EY · contact PI
Molecular Targets for the Prevention and Treatment of Kaposi's Sarcoma$273,686
R01 · FY2011 · CA · contact PI
Molecular Targets for the Prevention and Treatment of Kaposi's Sarcoma$282,150
R01 · FY2010 · CA · contact PI
Molecular Targets for the Prevention and Treatment of Kaposi's Sarcoma$282,150
R01 · FY2009 · CA · contact PI
Molecular Targets for the Prevention and Treatment of Kaposi's Sarcoma$282,150
R01 · FY2008 · CA · contact PI
Molecular Targets for the Prevention and Treatment of Kaposi's Sarcoma$282,150
R01 · FY2007 · CA · contact PI